Epithelial Ovarian Cancer research hub

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

The CATALINA-2 study is investigating a new drug called TORL-1-23 for women with advanced ovarian, primary peritoneal, or fallopian tube cancer that has stopped responding to platinum-based chemotherapy. It aims to see how safe and effective this new treatment is.